For the 2019 annual awards, the VIA Committee will select 1 to 4 projects for grants up to a total value of EUR 750,000.
The application process will be as follows:
phase-1LETTER OF INTENT (LOI)
Applicant downloads LOI form from VIA website
Applicant submits completed LOI via email
VIA Committee reviews submitted LOIs against selection criteria
VIA Committee shortlists approximately 10 LOIs compliant with selection criteria to proceed to phase 2 of the application process and the submission of a full proposal
VIA Committee invites shortlisted LOI applicants to submit an FP. Guidelines will be provided to the shortlisted applicants
Applicant submits FP as a Word document via email
VIA Committee reviews FPs against selection criteria
VIA Committee selects 1 - 4 FPs for a grant award, with a combined total value up to EUR 750,000
VIA Committee provides feedback to all FP applicants
VIA Committee announces details of selected project(s) awarded a grant
Applications are welcome from medical or research centres with a demonstrated record of research and achievement in CF.
Applications are welcome from single centres or multi-centres participating in collaborative research. For all applications, however, a lead investigator centre needs to be nominated.
Applications will be eligible from centres in all countries provided the lead investigator centre is from one of the following countries:
Applications from centres in countries that are not listed above are most welcome provided that they partner with a centre from one of the above listed countries which will act as the lead centre.
Applicants should be able to demonstrate that the proposed research will be led by an individual (or individuals) with an established career interest in CF and that they hold an MD, PhD or equivalent degree at the time of the application.
Applicants should be able to complete the proposed research within a 2-year award period, providing interim evidence to the VIA Committee approximately every 6 months, according to their project milestones. The VIA Committee will confirm the reporting requirements at the selection of the final project. Applications should also show the ability to follow local and international requirements (ICH).
All applications need to be supported by the institution hosting the research. An authorised signatory will be required for the submission of the Letter of Intent application.
Grants awarded under this programme should not duplicate funding from other government, non-governmental or industry sources. In addition, applications will not be accepted from members or centres of members of the VIA Committee.
The communication, review and selection of applicants and their applications is undertaken by the VIA Committee. Vertex remains independent of the entire application and selection process and has no communication with applicants until the final candidates are selected by the VIA Committee.
Applications will be reviewed and scored by the VIA Committee using a score card according to the following selection criteria:
A. Quality of proposal idea (30% weighting)
Innovation of research; feasibility of research; alignment to the VIA programme's research focus
B. Ability of the PI/Group to deliver the project (30% weighting)
Experience and record of executing research projects of comparable scope, expertise, time, budget; experience and record of research centre in therapy area; quality and availability of resources; adherence to ethical principles; design, execution and monitoring of the research by the principal investigator; reasonable approach to budget
C. Impact of project on understanding or treatment of CF (40% weighting)
7 September 2018
Letter of Intent (LOI) application period opens
9 November 2018
LOI application period closes (24:00 PST)
Communication to shortlisted LOI applicants and circulation of Full Proposal (FP) application form
29 March 2019
FP application period closes (24:00 PST)
Communication to successful applicant(s)
Timelines may change at the discretion of the VIA Secretariat and all applicants/potential applicants will be notified accordingly.